This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
San Diego-based venture investment fund Avalon Ventures has made a seed investment in a developer of a social shopping service, LoopIt , according to the companies. and is a spinout of Redstar Ventures, a venture incubator firm in Cambridge. Avalon's Rich Levandov was involved in the investment.
San Diego-based biotech investor Avalon Ventures has scored an exit, saying late Tuesday evening that it has entered into a definitive agreement with GlaxoSmithKline (GSK), to sell Sitari Pharmaceuticals to GSK. Sitari was developing treatments for celiac disease, and was being incubated at COI Pharmaceuticals.
Another of the biopharma startups created as part of a collaboration between San Diego investment firm Avalon Ventures and GlaxoSmithKline has been acquired—but not by GSK. Debuting in COI (which stands for “community of innovation”). Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
San Diego-based COI Pharmaceuticals , the life sciences incubator and support entity created by Avalon Ventures to support its portfolio companies, says that one of its companies, Calporta Therapeutics , has been acquired by Merck. The deal is worth up to $576M, including upfront payments and contingent milestone payments.
The company appears to be another company emerging from COI Pharmaceutiacls , the life sciences incubator and support entity created by Avalon Ventures to support its portfolio companies, as Sanford Madigan, Jay Lichter, and Tighe Reardon are all listed as officers of the new company. in funding--in what looks to be an ongoing $5.7M
Also participating in the funding was Avalon Ventures, New Enterprise Associates, and angels, including Kevin Plank (Under Armour) and Paul Palmieri (Millennial Media). Oien was previously the CEO of Chumby; ScoreStream is part of the EvoNexus incubator. READ MORE>>.
San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups). Lilly Asia Ventures, Osage University Partners, and Vivo Capital joined in the deal, according to a statement from Avalon. 9/27/16, 2:09 p.m. Bregua Corp.,
Plug and Play San Diego, established in 2013 as a satellite of the Sunnyvale, CA-based incubator, has funneled 15 local startups through the Silicon Valley program after providing some coaching and other services in San Diego. It’s really cool.”. Reprints | Share: UNDERWRITERS AND PARTNERS.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content